Forte Capital LLC ADV Takes Position in Roche Holding AG (OTCMKTS:RHHBY)

Forte Capital LLC ADV purchased a new position in Roche Holding AG (OTCMKTS:RHHBY) during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 8,916 shares of the company’s stock, valued at approximately $323,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. First Horizon Advisors Inc. grew its position in Roche by 39.4% in the 3rd quarter. First Horizon Advisors Inc. now owns 1,724 shares of the company’s stock worth $58,000 after purchasing an additional 487 shares during the last quarter. Altrius Capital Management Inc increased its position in Roche by 2.5% in the 3rd quarter. Altrius Capital Management Inc now owns 171,062 shares of the company’s stock valued at $5,804,000 after acquiring an additional 4,232 shares during the period. Enterprise Financial Services Corp bought a new stake in Roche during the 3rd quarter valued at $288,000. Paradigm Asset Management Co. LLC boosted its position in Roche by 18.4% during the 3rd quarter. Paradigm Asset Management Co. LLC now owns 5,151 shares of the company’s stock worth $175,000 after acquiring an additional 800 shares during the period. Finally, Tower Bridge Advisors bought a new position in shares of Roche in the third quarter worth $2,811,000.

Roche Price Performance

Shares of Roche stock traded up $0.57 during midday trading on Friday, reaching $29.83. 4,829,456 shares of the company’s stock traded hands, compared to its average volume of 4,474,277. Roche Holding AG has a 52 week low of $29.20 and a 52 week high of $40.48. The company’s 50 day simple moving average is $31.62 and its 200 day simple moving average is $33.44. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.75.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on RHHBY shares. Morgan Stanley cut Roche from an “equal weight” rating to an “underweight” rating in a report on Tuesday, January 16th. Argus restated a “hold” rating on shares of Roche in a report on Monday, March 4th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has assigned a buy rating to the stock. According to MarketBeat.com, Roche presently has a consensus rating of “Hold” and an average target price of $40.00.

Roche Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.